Eastgate Biotech (ETBI) 10-Q 2013 Q3 Quarterly report

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

[X]

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

For the Quarter Ended September 30, 2013

[   ]

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

For the transition period from           to           

Commission File Number  000-52886

EASTGATE ACQUISITIONS CORPORATION

(Exact name of registrant as specified in its charter)

Nevada  

87-0639378

(State or other jurisdiction of

(I.R.S. Employer Identification No.)

incorporation or organization)

2681 East Parleys Way, Suite 204, Salt Lake City, Utah 84109

(Address of principal executive offices)

(801) 322-3401

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes  [X]   No  [  ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).                   Yes  [  ]    No  [   ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company

Large accelerated filer

[  ]

Accelerated filer

[  ]

Non-accelerated filer

[  ]

 Smaller reporting company

[X]

(Do not check if a smaller reporting company)

     Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).   

Yes  [  ]   No  [X]

APPLICABLE ONLY TO CORPORATE ISSUERS

Indicate the number of shares outstanding of each of the issuer's classes of common equity, as of the latest practicable date.

Class

Outstanding as of November 13, 2013

Common Stock, $0.00001 par value

       31,625,000

TABLE OF CONTENTS

Heading

Page  

PART  I    —   FINANCIAL INFORMATION

Item 1.

Consolidated Financial Statements

4

Item 2.

Management's Discussion and Analysis of Financial Condition and Results

of Operations

11

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

16

Item 4.

Controls and Procedures

16

PART II   —   OTHER INFORMATION

Item 1.

Legal Proceedings

17

Item 1A.

Risk Factors

17

Item 2

Unregistered Sales of Equity Securities and Use of Proceeds

17

Item 3.

Defaults Upon Senior Securities

17

Item 4.

Mine Safety Disclosures

17

Item 5.

Other Information

17

Item 6.

Exhibits

17

Signatures

18

2

PART  I   —   FINANCIAL INFORMATION

Item 1.

Consolidated Financial Statements

The accompanying unaudited consolidated balance sheet of Eastgate Acquisitions Corporation at September 30, 2013, related unaudited consolidated statements of operations and cash flows for the nine months ended September 30, 2013 and 2012 and the period from September 8, 1999 (date of inception) to September 30, 2013, have been prepared by management in conformity with United States generally accepted accounting principles.  In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations and financial position have been included and all such adjustments are of a normal recurring nature.  It is suggested that these financial statements be read in conjunction with the financial statements and notes thereto included in the Company’s December 31, 2012 audited financial statements.  Operating results for the period ended September 30, 2013, are not necessarily indicative of the results that can be expected for the fiscal year ending December 31, 2013 or any other subsequent period.

3

EASTGATE ACQUISITIONS CORPORATION
(A Development Stage Company)
Consolidated Balance Sheets
ASSETS
			September 30,		December 31,
			2013		2012
			(Unaudited)
CURRENT ASSETS
	Cash			26,444		100,000
	Prepaid Assets		$	-	$	4,500
		Total Current Assets		26,444		104,500
PROPERTY & EQUIPMENT, net				57,730		-
LONG TERM DEPOSITS				17,625		-
		Total Long Term Assets		75,355		-
		TOTAL ASSETS	$	101,799	$	104,500
LIABILITIES AND STOCKHOLDERS' DEFICIT
CURRENT LIABILITIES
	Accounts payable		$	419,024	$	229,250
	Current portion of capital lease obligation			34,403		-
	Accrued interest - related parties			74,641		35,155
	Notes payable - related parties			817,690		449,103
		Total Current Liabilities		1,345,758		713,508
STOCKHOLDERS' DEFICIT
	Common stock;100,000,000 shares authorized,
	at $0.00001 par value, 31,625,000 and 31,625,000
	shares issued and outstanding, respectively			316		316
	Additional paid-in capital			134,884		134,884
	Accumulated other comprehensive income			1,254		-
	Deficit accumulated during the development stage			(1,380,413)		(744,208)
		Total Stockholders' Deficit		(1,243,959)		(609,008)
		TOTAL LIABILITIES AND STOCKHOLDERS'
		DEFICIT	$	101,799	$	104,500
The accompanying notes are an integral part of these condensed consolidated financial statements

4

EASTGATE ACQUISITIONS CORPORATION
(A Development Stage Company)
Consolidated Statements of Operations and Comprehensive Loss
(Unaudited)
											From Inception on
											September 8,
			For the Three Months Ended				For the Nine Months Ended				1999 Through
			September 30,				September 30,				September 30,
			2013		2012		2013		2012		2013
REVENUES			$	-	$	-	$	-	$	-	$	-
OPERATING EXPENSES
	Professional fees			13,370		-		26,677		111,459		143,551
	Research and development			44,757		38,684		107,503		59,127		212,925
	General and administrative			158,673		121,412		449,711		218,408		937,410
	Marketing and selling			9,327		-		9,327		-		9,327
		Total Operating Expenses		226,127		160,096		593,218		388,994		1,303,213
LOSS FROM OPERATIONS				(226,127)		(160,096)		(593,218)		(388,994)		(1,303,213)
OTHER EXPENSES
	Interest expense			(18,064)		(5,628)		(42,987)		(8,600)		(77,200)
		Total Other Expenses		(18,064)		(5,628)		(42,987)		(8,600)		(77,200)
LOSS BEFORE INCOME TAXES				(244,191)		(165,724)		(636,205)		(397,594)		(1,380,413)
PROVISION FOR INCOME TAXES				-		-		-		-		-
NET LOSS			$	(244,191)	$	(165,724)	$	(636,205)	$	(397,594)	$	(1,380,413)
BASIC LOSS PER SHARE			$	(0.01)	$	(0.01)	$	(0.02)	$	(0.02)
WEIGHTED AVERAGE
NUMBER OF COMMON SHARES
OUTSTANDING				31,625,000		31,625,000		31,625,000		21,260,036
COMPREHENSIVE LOSS
	A summary of the components of
	other comprehensive loss for the
	periods ended is as follows:
Net Loss			$	(244,191)	$	(165,724)	$	(636,205)	$	(397,594)	$	(1,380,413)
Other Comprehensive Income				1,291		-		1,254		-		1,254
	Comprehensive Loss		$	(242,900)	$	(165,724)	$	(634,951)	$	(397,594)	$	(1,379,159)
The accompanying notes are an integral part of these condensed consolidated financial statements

EASTGATE ACQUISITIONS CORPORATION
(A Development Stage Company)
Consolidated Statements of Cash Flows
(Unaudited)
								From Inception on
								September 8,
				For the nine Months Ended				1999 Through
				September 30,				September 30,
				2013		2012		2013
OPERATING ACTIVITIES
	Net loss			$	(636,205)	$	(397,594)	$	(1,380,413)
	Adjustments to reconcile net loss to net cash
	used by operating activities:
		Expenses paid on the Company's behalf
		by a related party			177,816		213,680		576,919
		Common stock issued for services			-		50,000		50,000
		Depreciation			10,461		-		10,461
		Services contributed by shareholders			-		3,000		34,700
	Changes in operating assets and liabilities:
		Accrued interest			39,486		8,600		74,641
		Prepaid asset			4,500		-		-
		Accounts payable			189,774		122,314		419,024
		Long term deposit			(17,625)		-		(17,625)
			Net cash used in Operating Activities		(231,793)		-		(232,293)
INVESTING ACTIVITIES
		Purchase of property and equipment			(4,648)		-		(4,648)
			Net Cash Used  in Investing Activities		(4,648)		-		(4,648)
FINANCING ACTIVITIES
		Payments on capital lease obligation			(29,140)				(29,140)
		Proceeds from notes payable to related parties			190,771		-		290,771
		Common stock issued for cash			-		-		500
			Net Cash Provided (used in) by Financing Activities		161,631		-		262,131
		NET INCREASE (DECREASE) IN CASH			(74,810)		-		25,190
		Effect of foreign currency translation adjustments			1,254				1,254
		CASH AT BEGINNING OF PERIOD			100,000		-		-
		CASH AT END OF PERIOD		$	26,444	$	-	$	26,444
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
	CASH PAID FOR:
		Interest		$	3,502	$	-	$	3,502
		Income Taxes		$	-	$	-	$	-
	NON CASH FINANCING ACTIVITIES:
		Capital contribution by officer - payment of
		related party payable on behalf of company		$	-	$	50,000	$	50,000
		Property & equipment purchased under
			capital lease obligation	$	63,543	$		$	63,543
The accompanying notes are an integral part of these condensed consolidated financial statements.

EASTGATE ACQUISITIONS CORPORATION

(A Development Stage Company)

Condensed Notes to Consolidated Financial Statements

September 30, 2013 and December 31, 2012

NOTE 1 - CONDENSED FINANCIAL STATEMENTS

The accompanying consolidated financial statements have been prepared by the Company without audit.  In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations, and cash flows at September 30, 2013, and for all periods presented herein have been made.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted.  It is suggested that these condensed financial statements be read in conjunction with the financial statements and notes thereto included in the Company's December 31, 2012 audited financial statements.  The results of operations for the periods ended September 30, 2013 and 2012 are not necessarily indicative of the operating results for the full years.

NOTE 2 - GOING CONCERN

The Company's consolidated financial statements are prepared using generally accepted accounting principles in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs and allow it to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable. If the Company is unable to obtain adequate capital, it could be forced to cease operations.

In order to continue as a going concern, the Company will need, among other things, additional capital resources. Management's plan is to obtain such resources for the Company by obtaining capital from management and significant shareholders sufficient to meet its minimal operating expenses and seeking equity and/or debt financing. However management cannot provide any assurances that the Company will be successful in accomplishing any of its plans.

The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and eventually secure other sources of financing and attain profitable operations. The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.

Recent Accounting Pronouncements

The Company has evaluated recent accounting pronouncements and their adoption has not had or is not expected to have a material impact on the Company’s financial position or statements.

Earnings (Loss) per Share

The Company has adopted ASC 260, “Earnings Per Share,” (“EPS”) which requires presentation of basic and diluted EPS on the face of the income statement for all entities with complex capital structures, and requires a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS computation.  In the accompanying financial statements, basic earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period.

The Company has no potentially dilutive securities, such as options or warrants, currently issued and outstanding.

EASTGATE ACQUISITIONS CORPORATION

(A Development Stage Company)

Condensed Notes to Consolidated Financial Statements

September 30, 2013 and December 31, 2012

         NOTE 3 – SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Comprehensive Loss

Comprehensive loss includes net loss as currently reported under U.S. GAAP and other comprehensive loss.  Other comprehensive loss considers the effects of additional economic events, such as foreign currency translation adjustments.

Research and Development Policy

Research and development costs are expensed as they are incurred.  Research and development expense was $107,503 and $59,127 for the nine months ended September 30, 2013 and 2012 and $212,925 from September 8, 1999 (inception) to September 30, 2013.

Consolidation Policy

The consolidated balance sheets and statement of operations and cashflows for the periods ended September 30, 2013 and December 31, 2012 include the books of Eastgate Acquisitions Corporation and its wholly owned subsidiary, Eastgate Pharmaceuticals Inc.  All intercompany transactions and balances have been eliminated in the consolidation.

Foreign Currency Policy

The Company’s wholly owned subsidiary, Eastgate Pharmaceuticals Inc.’s functional currency is the Canadian Dollar. All of its balance sheet accounts were translated to US Dollars at the September 30, 2013 spot rate. All of its income statement accounts were translated at the average translation rate between US Dollars and Canadian Dollars for the nine month’s ended September 30, 2013.

Property and Equipment Policy

Laboratory equipment and other equipment are stated at cost less accumulated depreciation.  Major renewals and improvements are capitalized: minor replacements, maintenance and repairs are charged to current operations.  Depreciation is computed by applying the straight-line method over the estimated useful lives which are generally five years.

	Method	Period
Laboratory and other equipment	Straight line	5 years

         NOTE 4 – RELATED-PARTY TRANSACTIONS

The Company has recorded loans from shareholders, amounts due to shareholders for expenses paid on its behalf by shareholders as Notes payable - related parties on the balance sheet. The amounts comprising Notes payable – related parties bear interest ranging from 5 percent per annum to 10 percent per annum are unsecured and are due and payable upon demand.  

-

During the year ended December 31, 2012, certain shareholders of the Company paid for expenses on behalf of the Company of $324,550. During 2012 in connection with the agreement to purchase patents from a related party (see Note 5 below), an officer and director of the Company agreed to pay $50,000 to a former officer thus reducing the amount owed to that former officer by $50,000. As consideration to the officer and director for this $50,000 payment on behalf of the Company, 10,000,000 shares of common stock were issued to the officer and director. The amount for patents purchased valued at $0 and the related party debt paid by the officer of $50,000 and has been recorded as contributed capital in equity (See Note 5).

8

EASTGATE ACQUISITIONS CORPORATION

(A Development Stage Company)

Condensed Notes to Consolidated Financial Statements

September 30, 2013 and December 31, 2012

         NOTE 4 – RELATED-PARTY TRANSACTIONS (CONTINUED)

-

During the nine months ended September 30, 2013, certain shareholders of the Company paid for expenses on behalf of the Company of $177,816 and advanced the Company $190,771.

-

During the year ended December 31, 2012, an officer of the Company loaned the Company $100,000, for operating expenses.

The resulting balance of Notes payable – related parties totaled $817,690 and $449,103 at September 30, 2013 and December 31, 2012, respectively.  The balance in interest accrued on the notes totaled $74,641 and $35,155 at September 30, 2013 and December 31, 2012, respectively.

NOTE 5 – STOCKHOLDERS’ EQUITY

During 2012, an officer of the Company contributed various administrative services to the Company, including basic management and accounting services, and utilization of office space and equipment. This officer resigned during 2012, resulting in no expense recorded beyond June 2012. These services have been valued at $500 per month of service and have been recorded as capital contributions of $0 and $3,000 as of the periods ending September 30, 2013 and December 31, 2012, respectively.

On May 22, 2012 pursuant to a patent acquisition agreement, the Company issued 10,000,000 shares of common stock valued at $0.005 per share to a Company officer in exchange for patent rights contributed, and forgiveness of debt to a related party of $50,000.  Also pursuant to the patent acquisition agreement, the Company issued an additional 10,000,000 shares of common stock to a third party in exchange for patent rights, valued also at $0.005 per share.

          NOTE 6 – PROPERTY & EQUIPMENT AND CAPITAL LEASE OBLIGATION

On January 4, 2013 the Company entered into a capital lease agreement to purchase equipment. The lease has a term of 19 months starting January 4, 2013 with the final payment due on August 1, 2014. The lease specifies a monthly rate of $3,600. The lease requires minimum lease payments of $68,400 over the term of the lease. The lease was initially recorded at $63,543, which is the present value of the minimum lease payments (less no executor cost) using the Company’s incremental borrowing rate of 10%.  During the nine months ended September 30, 2013 the Company paid principal of $29,140 ($0 during 2012) against the capital lease obligation and corresponding interest of $3,260, leaving an amount owing at the end of the period of $34,403 ($0 at December 31, 2012), $0 of which is a long-term obligation.  

Pursuant to ASC 840-30 for capital leases, the equipment was recorded at the same value as the initial capital lease obligation of $63,543.  Also during the nine months ending September 30, 2013, the Company purchased additional equipment for cash of $4,648. The estimated useful life of all equipment purchased during the period ended September 30, 2013 is 5 years. Depreciation expense of $10,461 and $0 was recorded during the nine months ended September 30, 2013 and September 30, 2012, respectively, which leaves a net balance in Property & Equipment of $57,730 and $0 at September 30, 2013 and December 31, 2012, respectively.

         NOTE 7 – LONG TERM DEPOSITS

During the third quarter the Company paid $17,625 in deposits for a tablet press to be used in the research and development department.  The equipment was received early in the fourth quarter and will be included in property and equipment on balance sheet.  

          NOTE 8 – SUBSEQUENT EVENTS

In accordance with ASC 855 Company management reviewed all material events through the date of this report and determined that there are no material subsequent events to report.

9

Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

The following information should be read in conjunction with the financial statements and notes thereto appearing elsewhere in this Form 10-Q.

Three months ended September 30, 2013 compared to the three months ended September 30, 2012 and for the nine months ended September 30, 2013 compared to the nine months ended September 30, 2012.

Recent Events

In January 2012 we entered into a Patent Acquisition Agreement (“Acquisition Agreement”) to acquire certain products, formulas, processes, proprietary technology and/or patents and patent applications related to pharmaceutical, nutraceutical, food supplements and consumer health products (collectively referred to as the “Acquired Products”).  The Acquisition Agreement was finalized and closed on May 22, 2012.

As a result of the acquisition of Acquired Products, we have become engaged in developing, formulating and ultimately commercializing innovative pharmaceutical, nutraceutical, food supplements and consumer health products. We intend to apply novel technologies for improvement of efficacy of the Acquired Products, based on natural or well-established compounds.  It is our intention to complete formulation of the Acquired Products and to ultimately market the commercialized products and compounds.

We are a development stage company with limited historical operations prior to finalizing the Acquisition Agreement.  We anticipate that in the immediate future, necessary funds to maintain our corporate viability will most likely be provided by officers, directors and/or principal stockholders.  Unless we are able to obtain adequate capital to fund operating losses until we become profitable, there is substantial doubt about our ability to continue as a going concern.

Forward Stock Split

In anticipation of closing the Acquisition Agreement, on March 6, 2012 we effected a forward stock split of Eastgate’s issued and outstanding shares of common stock on a 7.75 shares for one share basis. Prior to the forward stock split, we had 1.5 million shares of common stock issued and outstanding, which increased to 11,625,000 shares following the split. Taking into consideration the issuance of shares pursuant to the Acquisition Agreement, we presently have issued and outstanding 31,625,000 shares of common stock.  All further references herein to our outstanding common stock will be on a post-split basis.

Results of Operations

The following selected comparative financial information has been derived from and should be read in conjunction with the company’s financial statements for the years ended December 31, 2012 and for the three and nine months ended September 30, 2013.

		For the Three Months Ended				For the Nine Months Ended
		September 30,				September 30,
			2013		2012		2013		2012
		$	-	$	-	$	-	$	-
Professional fees			13,370		-		26,677		111,459
Research and development			44,757		38,684		107,503		59,127
General and administrative			158,673		121,412		449,711		218,408
Marketing and selling			9,327		-		9,327		-
	Total Operating Expenses		226,127		160,096		593,218		388,994
			(226,127)		(160,096)		(593,218)		(388,994)
Interest expense			(18,064)		(5,628)		(42,987)		(8,600)
	Total Other Expenses		(18,064)		(5,628)		(42,987)		(8,600)
			(244,191)		(165,724)		(636,205)		(397,594)
			-		-		-		-
		$	(244,191)	$	(165,724)	$	(636,205)	$	(397,594)

Revenues

We have not recorded any revenues since inception. Management anticipates that we will realize revenues during the fourth quarter of 2013, as we are able to develop our intellectual property and begin marketing new products.  

11

During the three month period ended September 30, 2013 (“third quarter”), we incurred a net loss of $244,191, an increase in loss of $78,467 when compared to our net loss of $165,724 for the third quarter of 2012.  The increase in net loss has resulted from the increase in operational activity in the third quarter of 2013. Whereas the loss in the third quarter of 2012 represent the cost associated with the patent acquisition agreement in May 2012.  During the nine month period ended September 30, 2013 (“first nine months”), we incurred a net loss of $636,205, an increase loss of $238,611 when compared to the $397,594 net loss for the comparable 2012 period. The increased loss for the first nine months of 2013 is primarily attributed to the start of operations after the patent acquisition agreement of May 2012. The individual expense explanations are detailed below.  The first nine months of 2013 represents operational activity for product development in order to begin marketing our new products.  Whereas the majority of operating expenses for the first nine months of 2012 represent the fees incurred in the acquisition of intellectual property in May 2012.

Operating Expenses

Professional fees

During third quarter ended September 30, 2013, professional fees expenses were $13,370, an increase of $13,370 from the third quarter of 2012 professional fees expense of $ 0.  The professional fees for the third quarter of 2013 represent operational activity with no unusual activity.  There was very little activity regarding professional fees in the third quarter of 2012 after extensive fees were incurred in the second quarter of 2012 resulting from the patent acquisition agreement in May 2102.  

During the first nine months of 2013, professional fees were $26,677 a decrease of $84,782 from $111,459 for the comparative nine months ended September 30, 2012. This decrease was primarily due to the fact that professional fees of 2013 represent normal operational activity whereas the nine month period ended September 30, 2012 included professional fees expenses related to the acquisition of the Acquired Products and to costs related to our periodic reporting obligations with the SEC.

Research and development

Research and development costs consist of fees paid to consultants for laboratory evaluation of product chemistry and formulation as well as tests and studies to assess the efficacy and potential safety of our products.  Also included in research and development are laboratory consumables.

During the third quarter ended September 30, 2013, research and development expenses of $44,757 increased by $6,073 form $38,684 for the third quarter of 2012. The increase was a result of the development work being done on our new products, which we anticipate will become available for sale in late 2013.

During the first nine months of 2013, research and development expenses of $107,503 increased by $48,376 from $59,127 for the comparable 2012 period. The increase was a result of the development of the new products, which we anticipate, will become available for sale in late 2013.

General and administrative

During the third quarter of 2013, we incurred general and administrative expenses of $158,673, an increase of $37,261 from $121,412 for the third quarter of 2012. The increase was a result of operations since the acquisition of intellectual property in May of 2012.

12

During the first nine months of 2013, we incurred general and administrative expenses of $449,711, an increase of $231,303 from $218,408 for the first nine months of 2012. The increase was a result of the start of operations since the acquisition of intellectual property in May of 2012.

Marketing and selling

During the third quarter of 2013, we incurred marketing and selling expenses of $9,327, an increase of $9,327 from $ 0 for the third quarter of 2012.  Marketing and selling expenses were incurred for the first time in anticipation of the start of sales in the fourth quarter of 2013.

During the first nine months of 2013, we incurred marketing and selling expenses of $9,327, an increase of $9,327 from $ 0 for the first nine months of 2012.  Marketing and selling expenses were incurred for the first time in anticipation of the start of sales in the fourth quarter of 2013.

Interest expense

Interest expense of $18,064 for third quarter of 2013 increased by $12,436 from the interest of $5,628 for the third quarter of 2012.  The increase interest expense reflects the increase in loans from stockholders to finance operations. The interest expense has not been paid and is carried on the balance sheet as a current liability accrued interest related party.   

Interest expense of $42,987 for the first nine months of 2013 increased by $34,387 from the interest of $8,600 for the comparable period of 2012.   The increase is attributed to an increase in loans from stockholders during the period.

In the opinion of management, inflation has not and will not have a material effect on our operations until such time as we successfully complete an acquisition or merger.  At that time, management will evaluate the possible effects of inflation related to our business and operations.

Liquidity and Capital Resources

At September 30, 2013 we had a working capital deficit of $1,319,314, which is an increase of $710,306 from the December 31, 2012 deficit balance of $609,008. The increased deficit is a result of beginning operations and a net loss for the first nine months of 2013 of $636,205.  Advances from a related party as well as an increase in accounts payable have financed our initial operations.

During the first nine months of 2013, ongoing expenses were paid by principal stockholders and through increasing accounts payable.  At September 30, 2013 and December 31, 2012, we had cash on hand of $26,444 and $100,000, respectively.  On October 23, 2012, the company entered into a demand promissory note agreement whereby we received $100,000 from a related party.  The note accrues interest at an annual rate of 5%, is unsecured and is payable on demand. At September 30, 2013 we had a note payable - related party of $817,690, compared to $449,103 at December 31, 2012.  The increase represents additional payment of ongoing expenses by related parties as well as advances from related parties during the first nine months of 2013.  Accrued interest – related party at September 30, 2013 was $74,641 compared to $35,155 at December 31, 2012, which increase reflects the added interest on the payable – related party.  Accounts payable increased from $229,250 at December 31, 2012, to $419,024 at September 30, 2013, reflecting an increase in unpaid obligations due to increased operations since finalizing the Acquisition Agreement.

At September 30, 2013, we had a stockholders’ deficit of $1,243,959 compared to a stockholders' deficit of $609,008 at December 31, 2012.  The increase in stockholders' deficit is primarily attributed to ongoing general and administrative expenses, additional professional fees, principally legal and accounting costs, and research and development expenses.

13

As of November 11, 2013, we had cash on hand of $3,810.  We believe that our available cash combined with continued advances from related party will be sufficient to carry on general corporate functions for the next three months, although we will need to limit cash outlays for research and product development until we can secure additional funds.  We are presently investigating possible funding opportunities to arrange for additional funds, although we do not have any definitive agreement or arrangement for such funds.  We expect that additional funding to proceed with development of the Acquired Products will most likely be from the sale of securities or from stockholder loans. We may not be successful in our efforts to obtain equity financing to carry out our business plan and there is doubt regarding our ability to complete our planned development program.  We estimate that cash requirements for the next twelve months will be approximately $5,000,000.  In the past year, we have relied on advances from related parties for financing our operations. We continue to explore potential funding opportunities, which may be in the form of debt or the sale of equity securities. In the event we are unsuccessful in arranging for outside funding, we will most likely continue to rely on related parties to provide funding, although there are no firm commitments or agreements with any related party to provide funds in the future.

Net Operating Loss

We have accumulated a net operating loss carryforward of approximately $290,241 as of December 31, 2012.  This loss carry forward may be offset against future taxable income through the year 2031.  The use of these losses to reduce future income taxes will depend on the generation of sufficient taxable income prior to the expiration of the net operating loss carryforwards.  In the event of certain changes in control, there will be an annual limitation on the amount of net operating loss carryforwards that can be used.  No tax benefit has been reported in the financial statements for the year ended December 31, 2012 or the nine month period ended September 30, 2013 because it has been fully offset by a valuation reserve.  The use of future tax benefit is undeterminable because we presently have no operations.

Recent Accounting Pronouncements

The company has evaluated recent accounting pronouncements and their adoption has not had nor is expected to have a material impact on the company’s financial position or statements.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to stockholders.

Plan of Operation

Following the closing of the Acquisition Agreement we have become engaged in the development and ultimate formulation of other novel formulations of natural compounds and OTC products that have limitations in effective use for human consumption.  We believe our self-emulsifying drug delivery technology can improve the efficacy of existing products and formulations based on natural or well-established compounds and known biologically active compounds. We intend to conduct our research and development through collaborative programs. We anticipate relying on arrangements with third party drug developers such as contract research organizations and clinical research sites for a significant portion of our product development efforts.

The Acquisition Agreement enabled us to acquire certain products, formulas, processes, proprietary technology and/or patents and patent applications related to pharmaceutical, nutraceutical, food supplements and consumer health products. We have not formulated any final products or received  approvals from any regulatory agencies or generated any revenues from product sales. We have not been profitable since our inception through the current date.

14

We expect to incur significant operating losses for the next several years and until we are able to formulate a commercially viable product.  We also expect to continue to incur significant operating and capital expenditures and anticipate that our expenses will increase substantially in the foreseeable future as we:

●

Continue to undertake formulation of novel products and subsequent preclinical and clinical trials for our product candidates;

●

Seek regulatory approvals for our product candidates;

●

Develop, formulate, manufacture and commercialize our products;

●

Implement additional internal systems and develop new infrastructure;

●

Acquire or in-license additional products or technologies, or expand the use of our technology;

●

Maintain, defend and expand the scope of our intellectual property; and

●

Hire qualified personnel.

Future product revenue will depend on our ability to develop, receive regulatory approvals for, and successfully market, our product candidates. In the event that our development efforts result in regulatory approval and successful commercialization of our product candidates, we will generate revenue from direct sales of our products and/or, if we license our products to future collaborators, from the receipt of license fees and royalties from licensed products.

Management estimates that our research and development expenses for the next 12 months will be approximately $4 million, primarily for research and pilot studies.  We also estimate that other expenses, including personnel, general and administrative and miscellaneous expenses could be as much as $1 million during the same time period.  Because we currently have no revenues, most likely the only source of funding these expenses will be through the private sale of our securities, either equity or debt.  We are currently exploring possible funding sources, but we have not entered into any arrangements or agreements for funding as of this time.  If we are unable to raise the necessary funding, our research and development plans will be delayed indefinitely.  There can be no assurance that we will be able to raise the funds necessary to carry out our business plan on terms favorable to the company, or at all.

Forward-Looking and Cautionary Statements

Statements contained in this report which are not historical facts, may be considered "forward-looking statements," which term is defined by the Private Securities Litigation Reform Act of 1995.  Any “safe harbor under this Act does not apply to a “penny stock” issuer, which definition would include the company.  Forward-looking statements are based on current expectations and the current economic environment.  We caution readers that such forward-looking statements are not guarantees of future performance. Unknown risks and uncertainties as well as other uncontrollable or unknown factors could cause actual results to materially differ from the results, performance or expectations expressed or implied by such forward-looking statements.

Item 3.

Quantitative and Qualitative Disclosures About Market Risk.

This item is not required for a smaller reporting company.

Item 4.

Controls and Procedures.

Evaluation of Disclosure Controls and Procedures.  Disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) are designed to ensure that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded,

15

processed, summarized and reported within the time periods specified in SEC rules and forms.  Disclosure and control procedures are also designed to ensure that such information is accumulated and communicated to management, including the chief executive officer and chief financial officer, to allow timely decisions regarding required disclosures.

As of the end of the period covered by this quarterly report, we carried out an evaluation, under the supervision and with the participation of management, including our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures.  In designing and evaluating the disclosure controls and procedures, management recognizes that there are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention or overriding of the controls and procedures.  Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their desired control objectives.  Additionally, in evaluating and implementing possible controls and procedures, management is required to apply its reasonable judgment.  Based on the evaluation described above, our management, including our chief executive officer and chief financial officer, concluded that, as of September 30, 2013, our disclosure controls and procedures were not effective due to a lack of adequate segregation of duties and the absence of an audit committee.

Changes in Internal Control Over Financial Reporting.  Management has evaluated whether any change in our internal control over financial reporting occurred during the first nine months of fiscal 2013. Based on its evaluation, management, including the chief executive officer and chief financial officer, has concluded that there has been no change in our internal control over financial reporting during the first nine months of 2013 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART  II   —   OTHER INFORMATION

Item 1.

Legal Proceedings

There are no material pending legal proceedings to which we are a party or to which any of our property is subject and, to the best of our knowledge, no such actions against us are contemplated or threatened.

Item 1A.

Risk Factors

This item is not required for a smaller reporting company.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

This Item is not applicable.

Item 3.

Defaults Upon Senior Securities

This Item is not applicable.

Item 4.

Mine Safety Disclosures

This Item is not applicable.

Item 5.

Other Information

This Item is not applicable.

Item 6.

Exhibits

Exhibit 31.1

Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

16

Exhibit 31.2

Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

Exhibit 32.1

Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

Exhibit 32.2

Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

Exhibit 101*

Interactive Data File

*

In accordance with Rule 406T of Regulation S-T, these XBRL (eXtensible Business Reporting Language) documents are furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, or Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under these sections.

17

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

          EASTGATE ACQUISITIONS CORPORATION

Date:  November 13, 2013

By: /S/   ANNA GLUSKIN

Anna Gluskin

Chief Executive Officer

(Principal Executive Officer)

Date:  November 13, 2013

By: /S/   BRIAN LUKIAN

Brian Lukian

Chief Financial Officer

(Principal Accounting Officer)

18